Sensorion halts development of SENS-501 for OTOF-related hearing loss after strategic review
read at Endpoints ↗Neutral
Sensorion announced it is ending the development of its SENS-501 candidate, which was aimed at treating OTOF-related hearing loss, following a strategic review of its pipeline.
The biotech said it will continue to pursue another hearing loss program, reallocating resources to areas it views as higher priority.
Separately, Novartis reported new biomarker data in muscular dystrophy, highlighting ongoing research efforts in that disease area.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy”
read at Endpoints ↗75 words · retrieved Jun 11
comments(0)
5-min edit window · permanent after that